Physician profile
Wendy Baca
NPI 1023016177
$4,858.81
in general payments reported to CMS, 2019-2025
18 companies · $994 in 2025
The $994 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $98.24 · 2021: $363 · 2022: $824 · 2023: $961 · 2024: $741 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,066.58 | 2019-2025 | |
| Alcon Vision LLC | $723.93 | 2021-2025 | Centurion, Clareon, Hydrus Microstent |
| Abbvie INC. | $653.83 | 2022-2023 | Durysta, Xen Glaucoma Treatment System |
| Allergan, INC. | $286.53 | 2019-2022 | |
| Amgen INC. | $275.82 | 2024-2025 | Tepezza |
| Genentech USA, INC. | $241.62 | 2019-2022 | |
| Ocular Therapeutix, INC. | $225.04 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $223.24 | 2019-2020 | |
| Sight Sciences, INC. | $136.96 | 2025 | Omni Surgical System |
| Astellas Pharma US INC | $127.12 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | Syfovre |
| Eyevance Pharmaceuticals LLC | $124.99 | 2021 | |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $116.71 | 2019 | |
| Nova Eye, INC. | $105.13 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $103.37 | 2019 | |
| Rxsight INC | $101.10 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Baca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.